|
Market Closed -
Nasdaq
23:00:00 26/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 3.580 USD | -7.97% |
|
+1.99% | -37.95% |
| 10-21 | Unicycive Therapeutics Shares Rise After FDA Accepts Resubmitted NDA | DJ |
| 10-21 | Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission | CI |
Company Valuation: Unicycive Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 30.84 | 8.148 | 30.16 | 82.44 | 124 | 99.72 | - | - |
| Change | - | -73.58% | 270.11% | 173.36% | 50.43% | -19.58% | - | - |
| Enterprise Value (EV) | 30.84 | 8.148 | 30.16 | 82.44 | 124 | 99.72 | 99.72 | 99.72 |
| Change | - | -73.58% | 270.11% | 173.36% | 50.43% | -19.58% | 0% | 0% |
| P/E | -2.4x | -0.45x | -0.68x | -1.42x | -3.46x | -2.83x | 2.2x | 0.44x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0x | -0.1x | 0x | 0x | 0.1x | -0x | 0x |
| Capitalization / Revenue | - | 8.57x | 44.7x | - | - | 72.8x | 0.72x | 0.18x |
| EV / Revenue | - | 0x | 0x | - | - | 72.8x | 0.72x | 0.18x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -2.62x | 1.67x | 0.27x |
| EV / FCF | -0x | - | -0x | -0x | -0x | -3.06x | -4.82x | 0.66x |
| FCF Yield | -18.8% | - | -60.7% | -34.8% | -25.3% | -32.7% | -20.8% | 152% |
| Dividend per Share 2 | - | - | - | - | - | - | 2.08 | 5.37 |
| Rate of return | - | - | - | - | - | - | 58.1% | 150% |
| EPS 2 | -8.6 | -12 | -12.8 | -5.6 | -1.67 | -1.266 | 1.624 | 8.06 |
| Distribution rate | - | - | - | - | - | - | 128% | 66.6% |
| Net sales 1 | - | 0.951 | 0.675 | - | - | 1.37 | 139 | 546.9 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -8.977 | -18.05 | -20.77 | -32.12 | -29.52 | -38.03 | 59.54 | 374.4 |
| Net income 1 | -10.02 | -18.06 | -31.41 | -37.82 | -26.56 | -35.38 | 51.53 | 355 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 20.600 | 5.400 | 8.677 | 7.942 | 5.770 | 3.580 | 3.580 | 3.580 |
| Nbr of stocks (in thousands) | 1,497 | 1,509 | 3,475 | 10,380 | 21,491 | 27,855 | - | - |
| Announcement Date | 3/31/22 A | 3/31/23 A | 3/28/24 A | 3/31/25 A | 3/30/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.83x | - | - | - | 99.72M | |
| 18.07x | 6.54x | 12.9x | 1.78% | 65.28B | |
| 30.04x | 7.96x | 26.09x | 0.05% | 54.57B | |
| 36.97x | 6.56x | 19.6x | 0.88% | 53.59B | |
| 34.86x | 3.39x | 14.64x | -.--% | 45.03B | |
| 48.82x | 5.62x | 30.9x | -.--% | 42.17B | |
| -19.09x | 184.46x | -20.29x | -.--% | 39.42B | |
| 28.28x | 8.04x | 20.81x | 0.38% | 32.71B | |
| 27.72x | 5.84x | 15.15x | -.--% | 24.01B | |
| 36.39x | 6.61x | 22.07x | -.--% | 26.5B | |
| Average | 23.92x | 26.11x | 15.76x | 0.34% | 38.34B | |
| Weighted average by Cap. | 26.69x | 24.66x | 15.94x | 0.46% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- UNCY Stock
- Valuation Unicycive Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
